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Olfactomedin (OLF) domain-containing proteins, first identified in relation to 
bullfrog olfactory chemoreception, are part of a superfamily of proteins implicated in 
many important biological functions and human diseases. The myocilin OLF domain 
(mOLF), one of the best studied, is closely associated with the ocular disease glaucoma. 
Nearly 100 myocilin mutations have been reported in glaucoma patients; >90% are 
missense mutations within mOLF. Disease-associated mutant myocilins are destabilized 
and aggregation prone, leading to toxicity and death of cells that maintain the anatomical 
trabecular meshwork extracellular matrix in the eye. The Lieberman lab solved the 
crystal structures of OLF domains from myocilin and gliomedin (gOLF), a peripheral 
nervous system OLF domain. While both are similar five-bladed β-propellers, only 
mOLF contains a stabilizing calcium ion. Remarkably, gOLF is ~20 °C more stable than 
mOLF, even though it doesn't have a calcium ion and is phylogenetically more primitive. 
The goal of this project was to use insights from mOLF and gOLF to create a 
thermostable mOLF. Surprisingly, mutagenesis of a calcium-coordinating aspartate 
(D478) to alanine abolished calcium binding but increased mOLF thermal stability to 
near gOLF levels. Addition of D478A to the destabilized, glaucoma-associated variant 
D380A rescued thermal stability to that of wild-type (WT) mOLF. Structures of 
thermostable mOLF variants reveal unexpected changes in tertiary structure compared to 
WT mOLF, which were confirmed by solution biophysical measurements. The findings 
from this study expand our understanding of the structure-stability relationship of mOLF 





Olfactomedin (OLF) domain-containing proteins were first discovered in 
bullfrogs as a glycoprotein involved olfactory chemoreception1 and are now a 
superfamily of proteins that have implications in important biological functions and 
human diseases. The best studied OLF domain-containing protein thus far is myocilin, 
which has been linked to the development of the ocular disease glaucoma2, the second 
leading cause of blindness worldwide3. The modular architecture of myocilin includes an 
N-terminal region that contains a leucine zipper motif and two coil-coil domains and a C-
terminal region that contains the OLF domain2, 4. More than 90% of glaucoma-associated 
missense mutations have been found to occur within the mOLF domain here2, 5, 
highlighting the biomedical importance of understanding structure-function relationships 
in mOLF.  
Primary open-angle glaucoma (POAG) is the most common form of glaucoma 
that is clinically presented as a loss of visual acuity accompanied with increased 
intraocular pressure (IOP)2. Currently, the exact cause of the elevated IOP is still 
unknown but the current leading pathology involves an increase in resistance of aqueous 
humor outflow from aggregation in the anterior of the eye within the trabecular 
meshwork (TM), which functions as a filter-like mechanism composed of extracellular 
matrix and endothelial-like cells2. Disease-causing nonsynonymous myocilin mutations 
expressed in the TM are prone to intracellular aggregation in the endoplasmic reticulum 
(ER), causing TM cell death, leading to reduced function of the TM fluid outflow, and, 
eventually, the onset of glaucoma6.  
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 An additional OLF domain-containing protein called gliomedin (gOLF) or 
collomin, has been classified as part of the most phylogenetically primitive OLF 
subfamily and has been found to be involved in peripheral nervous system (PNS) 
development7-10. The domain architecture of gliomedin includes a type II transmembrane 
domain and an extracellular region with two collagen domains and its OLF domain9. 
After gliomedin is synthesized in the ER of Schwann cells, the extracellular region is 
cleaved from the membrane via a RNKR-furin recognition site which then forms a trimer 
via the collagen domains10-11 that allows for the OLF domain to bind the fibronectin-III-
like domains of neurofascin 186 (NF186) and neuronal cell adhesion molecules 
(NrCAM)10-12. These two CAMs accumulate at heminodal clusters of peripheral neurons 
to recruit voltage-gated sodium channels13 and thus lead to the formation and 
maintenance of the nodes of Ranvier for fast saltatory conduction in myelinated nerves14.  
Our lab has solved the crystal structures for both mOLF and gOLF which 
revealed similar five-bladed β-propeller structures15-16. The β-propeller is composed of 
blades, each containing a four-stranded antiparallel β-sheet, that form a circular 
arrangement around a central hydrophilic channel for ligand coordination or catalytic 
functions17. Propellers are most notable for their unique motifs, including the so-called 
molecular Velcro interactions that stabilize the N- and C- termini in the closed circular 
arrangement. Biologically, propellers are typically involved in protein-protein or protein-
ligand interactions18.  
Structural overlay for comparison of mOLF and gOLF structures (Fig 1.1) did not 
immediately reveal marked differences between the two polypeptide chains; however, the 
central channels of the two structures contained differences in metal binding sites16, 19 
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(Fig 1.2). In mOLF, the central hydrophilic channel of its β-propeller contains a 7-
coordinate, stabilizing, calcium ion that was identified prior to the structure by metal 
analysis15, 19 and an apparent sodium ion adjacent to the calcium at a distance of ~3.4 Å15. 
Surprisingly, gOLF does not contain a coordinated calcium ion yet is ~20°C more stable 
than mOLF, and it is phylogenetically more primitive7, 16. In line with its high thermal 
stability, gOLF is also more resistant than mOLF to chemical unfolding 16.  
 
Figure 1.1. Overlay of mOLF (light orange, PDB 4WXU) and gOLF (teal, PDB 4XAV) 
structures. In general, the OLF domain-containing proteins appear to have a very similar 
five-bladed β-propeller structure. 
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(a)  (b)  
Figure 1.2. Metal binding sites of (a) mOLF and (b) gOLF16. The hydrophobic β-
propeller of mOLF contains a key calcium binding site that has been found to be 
implicated in thermal stability of the mOLF protein. The hydrophobic β-propeller of 
gOLF only contains a sodium ion in the core and does not have a novel calcium ion that 
is important for proper protein folding and stability. Lower panels show the interacting 
distances measured in Å. Reprinted by permission from PLOS ONE Publishing Group. 
 The surprising differences between mOLF and gOLF beg the question of why 
animals have mOLF in the eye where mutations, sustained UV exposure, and other 
environmental and mechanical stressors lead to myocilin aggregation, when a variant 
more similar to gOLF could, in theory, be resistant to these stressors16? The origin of the 
differing thermal stability between mOLF and gOLF appears to be due to metal binding 
sites located in the central cavity, which function as a tether for the blades in the β-
propeller. The calcium binding site of mOLF is coordinated to the side chains of Asp380 
(D380), Asn428 (N428), and Asp478 (D478) all in a monodentate fashion15-16. The 
sodium ion found in mOLF, adjacent to the calcium binding site, is coordinated by the 
side chains of aggregation-prone D380, D478, and Leu381 (L381)15-16. The D380A 
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variant is annotated as glaucoma-causing, destabilized from WT mOLF by ~7 °C, and 
calcium ion binding is abolished15, 19. Though variants of mOLF residue D478 have not 
yet been identified in populations, based on the same principles of metal ion stabilization, 
mutagenesis of the D478 residue was predicted to destabilize mOLF. As an alternative to 
cation binding, increased hydrophobic interactions, which have been suggested to also 
have a role in structural stability of the β-propeller20, could also be at play in thermally 
stabilizing gOLF over mOLF. Indeed, when comparing hydrophobic interactions of 
gOLF with other OLF domains, there are 20 more hydrophobic interactions in gOLF16.  
Here we report the steps that led to thermostable variants of mOLF, based on 
insights on metal binding sites and nonconserved residues between gOLF, mOLF, and 
other related OLF domain-containing proteins. Mutagenesis of the calcium-coordinated 
D478 residue to a serine resulted in knockout of calcium ion binding but, surprisingly, 
was accompanied by an increase in mOLF thermal stability to near gOLF levels. 
Simultaneous mutagenesis of D478S with the disease-causing D380A variant resulted in 
knockout of calcium binding within the central cavity and rescued thermal stability of the 
mOLF variant. Structures of the thermally stable mOLF variants revealed unexpected 
changes in tertiary structure compared to WT mOLF, which were confirmed by solution 
biophysical measurements. The findings presented in this study lay the groundwork for 
structural-stability studies of mOLF and expand our knowledge on insight into the 
evolution of the OLF β-propeller. 
 6 
CHAPTER 2 
RATIONAL MUTAGENESIS TO INCREASE THERMAL 
STABILITY OF MOLF BY INCREASING HYDROPHOBICITY 
Introduction 
 Evolutionary trace analysis across all OLF domains was conducted by Dr. Raquel 
Lieberman and then mapped onto the mOLF structure to assess trends in sequence 
conservation that could expand our knowledge on molecular characteristics among the 
OLF family of proteins. The evolutionary trace analysis was further analyzed by Dr. 
Shannon Hill for sequence differences among olfactomedin 1 (OLFM1), olfactomedin 4 
(OLFM4), gOLF, and mOLF. Preliminary comparison of thermal stability, measured by 
melting temperature (Tm), among mOLF, OLFM4, and OLFM1 revealed that the Tm for 
OLFM4 is lower and that of OLFM1 is higher than mOLF16. Interestingly, gOLF exhibits 
the highest sequence divergence compared to these other OLFs, and in particular, gOLF 
exhibits a noticeable increase in hydrophobic amino acid residues compared to mOLF16. 
Hydrophobic interactions have been suggested to contribute significantly to the stability 
of the β-propeller structure20 leading to the hypothesis that the high thermal stability 
associated with gOLF could be due to the more abundant hydrophobic interactions within 
the structure16. To test this hypothesis, non-glaucoma-associated single point mutations 
corresponding to the aligned gOLF residue were introduced into mOLF.  Proteins were 
expressed, purified, and analyzed for an increase in Tm value via differential scanning 
fluorimetry (DSF). 
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Protein Engineering of mOLF Variants using Site-Directed Mutagenesis 
 Initial variants for mOLF thermal stability testing were chosen to increase 
hydrophobic interactions for structural stability folding of the mOLF β-propeller based on 
sequence alignments with gOLF. Site-directed mutagenesis (SDM) on wild type (WT) 
maltose-binding protein (MBP)-mOLF was conducted to obtain the following single-
mutation mOLF variants: MBP-mOLF G456L, D378Y, S404A, K358L, T455L, and 
F307L. Mutated plasmids were confirmed by DNA sequencing aligned with WT MBP-
mOLF. Point mutations are highlighted in the sequence alignments provided for each 
MBP-mOLF variant. 
WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
G456L       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
G456L       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
G456L       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
            ************************************************************ 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
G456L       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTLTGISKTLTIPF  
            ************************************************ *********** 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
G456L       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
            ************************************* 
Figure 2.1. DNA sequencing results for MBP-mOLF(G456L) plasmid. Raw data can be 
found in notebook #2 on pages 24 and 25. 
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WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
D378Y       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
D378Y       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN  
D378Y       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTYIDLAVDEAGLWVIYSTDEAKGAIVLSKLN  
            ****************************** ***************************** 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
D378Y       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
            ************************************************************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
D378Y       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
            ************************************* 
Figure 2.2. DNA sequencing results for MBP-mOLF(D378Y) plasmid. Raw data can be 
found in notebook #2 on pages 54 through 56. 
 
WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
S404A       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
S404A       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN  
S404A       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLAKLN  
            ********************************************************:*** 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
S404A       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
            ************************************************************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
S404A       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
            ************************************* 
Figure 2.3. DNA sequencing results for MBP-mOLF(S404A) plasmid. Raw data can be 
found in notebook #2 on pages 26 and 27. 
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WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
K358L       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
K358L       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN  
K358L       ELNTETVKAELEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN  
            ********** ************************************************* 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
K358L       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
            ************************************************************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
K358L       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
            ************************************* 
Figure 2.4. DNA sequencing results for MBP-mOLF(K358L) plasmid. Raw data can be 
found in notebook #2 on pages 39 and 40. 
 
WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
T455L       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
T455L       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN  
T455L       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN  
            ************************************************************ 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
T455L       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDLGTGISKTLTIPF  
            *********************************************** ************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
T455L       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
            ************************************* 
Figure 2.5. DNA sequencing results for MBP-mOLF(T455L) plasmid. Raw data can be 
found in notebook #2 on pages 56 through 58. 
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WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
F307L       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
F307L       IDTVGTDVRQVFEYDLISQLMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
            *******************:**************************************** 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
F307L       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
            ************************************************************ 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
F307L       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
            ************************************************************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM 
F307L       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM 
            ************************************* 
Figure 2.6. DNA sequencing results for MBP-mOLF(F307L) plasmid. Raw data can be 
found in notebook #2 on pages 109 through 112. 
 
Purification of MBP-mOLF Variants 
 Growth expression yields for MBP-mOLF variants ranged between 7 g/L and 10 
g/L (Table 2.1). Small scale protein purification for each variant involved lysing 3g of 
MBP-mOLF containing E. coli cell paste followed by affinity and size-exclusion 
chromatography. An amylose affinity column was used to isolate the fusion protein 
MBP-mOLF variants followed by a size exclusion polishing step using a Superdex 75 
(sup75) column. Purity was assessed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) (Fig 2.8-2.9). MBP-mOLF fusion protein variants were 
concentrated and buffer-exchanged in the appropriate HEPES buffer for thermal stability 
experiments. Overlayed sup75 traces of MBP-mOLF variants are provided in Figure 2.7. 
The first peak in the chromatograms represents aggregated protein and the second peak 
consists of fusion protein with monomer and free maltose. These fusion protein variants 
were not further cleaved with Factor Xa to remove the MBP-tag. Purified protein yields 
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ranged from 0.081 mg/g cell paste for MBP-mOLF(D378Y) to 1.763 mg/g cell paste for 
MBP-mOLF(G456L). 
Table 2.1. Growth expression yields and protein expression yields for MBP-mOLF 
variants. 
Olfactomedin Domain Cell Paste Yield (g/L) Protein Yield (mg/g cell paste) 
MBP-mOLF(G456L) 7.6 1.763 
MBP-mOLF(D378Y) 6.8 0.081 
MBP-mOLF(S404A) 7.4 0.273 
MBP-mOLF(K358L) 7.9 0.488 
MBP-mOLF(T455L) 11.0 0.266 
MBP-mOLF(F307L) 7.0 0.932 
 
 
Figure 2.7. Overlay of sup75 chromatograms for fusion mOLF variants for increasing 
hydrophobic interactions. The first eluted peaks are MBP-mOLF aggregates and the 
second eluted peaks contained fusion MBP-mOLF protein. 
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(a.) (b.)  
Figure 2.8. (a.) MBP-mOLF(D378Y) and (b.) MBP-mOLF(S404A) purification 
assessment from size exclusion chromatography on sup75 column by 12% resolving gel. 
MBP is represented by the band at 45 kDa and fusion MBP-mOLF variant protein is 
represented by bands around 66 kDa. MBP-mOLF(D378Y) was observed to have very 
little fusion protein yield. Fractions 14 and 15 were used for MBP-mOLF(D378Y) 
thermal stability assessments. Fractions 13 and 14 were used for MBP-mOLF(S404A) 
thermal stability assessments. 
(a.) (b.)
(c.)  
Figure 2.9. (a.) MBP-mOLF(K358L), (b.) MBP-mOLF(T455L), and (c.) MBP-
mOLF(F307L) purification assessment from size exclusion chromatography on sup75 
column by 12% resolving gel. MBP is represented by the band at 45 kDa and fusion 
MBP-mOLF variant protein is represented by bands around 66 kDa. Fractions 13 and 14 
were used for MBP-mOLF(K358L) thermal stability assessments. Fractions 7 and 8 were 
used for MBP-mOLF(T455L) thermal stability testing. Fractions 7 and 8 were used for 




 The six purified MBP-mOLF variants were evaluated for thermal stability via 
DSF. Tm values of MBP-mOLF variants were used to assess thermal stability associated 
with the change in hydrophobicity. All MBP-mOLF variants resulted in slight thermal 
destabilization except for MBP-mOLF(D378Y) resulting in severe thermal 
destabilization compared to WT. Decreased stabilization from MBP-mOLF(K358L) was 
likely due to alterations in the conformation of the B-10/C-11 loop which is thought to 
serve as an access gate to the central cavity of the β-propeller since the mutation occurred 
right before the loop15. Severe decrease in thermal stabilization from MBP-
mOLF(D378Y) reflected the degree of destabilization associated with mOLF(K423E) 
when cation-π interactions were disrupted15. Since the analyzed mutations did not disrupt 
ion binding, the six MBP-mOLF variants exhibited increased thermal stabilization in the 
presence of calcium. 
Table 2.2. Thermal stability testing of mOLF variants prior to cleavage with Factor Xa 
using DSF. gOLF and mOLF Tm values were measured after cleavage with Factor Xa. 
Mutations were chosen to increase hydrophobic interactions for increased folding 
stability. Tm values were not found to significantly increase the thermal stability of 
mOLF.  
 
Olfactomedin Domain Tm (°C) ΔTm + Ca2+ 
gOLF 69.7 ± 0.1 -0.4 
mOLF 51.7 ± 0.3 +7.2 
MBP-mOLF(G456L) 50.8 ± 0.1 +10.1 
MBP-mOLF(D378Y) 38.6 ± 0.1 +10.1 
MBP-mOLF(S404A) 48.4 ± 0.2 +9.2 
MBP-mOLF(K358L) 48.3 ± 0.2 +9.6 
MBP-mOLF(T455L) 47.2 ± 1.2 +7.4 




MUTAGENESIS OF CALCIUM BINDING SITE INCREASED 
THERMAL STABILITY OF mOLF 
Introduction 
 In addition to differences in hydrophobic content discussed in Chapter 2, the β-
propeller structures of gOLF and mOLF also differ in metal content. The β-propeller 
structure of mOLF contains a sodium and calcium ion with key amino acid residues 
coordinated with the metal ions (Fig 1.2a). The calcium ion in mOLF is key to the 
structural stability and proper folding of the protein. Coordinating amino acid residues, 
such as D380 and isoleucine 477 (I477), are mutated in glaucoma patients and these 
mutants decrease thermal stability of mOLF19. By comparison, there is no calcium ion 
present in the gOLF β-propeller (Fig 1.2b) yet gOLF is about 20°C more stable than WT 
mOLF. In place of calcium- and sodium- coordinating D478 in mOLF is a non-
coordinating asparagine residue in gOLF. This chapter focuses effects of mutating D478 
on the structure and stability of mOLF. Because of its similarity to disease-causing D380, 
mutation of D478 was predicted to abrogate metal binding and thus destabilize mOLF. 
Interestingly, the results indicate the opposite stability effect with striking structural 
consequences. 
Mutational strategy to abolish metal binding in mOLF 
 Multiple sequence alignment of OLF family members reveals that the region 
responsible for metal binding differs somewhat across OLF domain-containing proteins. 
Whereas calcium ligands D380 and N428 in mOLF are largely conserved, D478 exhibits 
more variation across OLFs (Fig 3.1). Prior studies conducted in the Lieberman lab on 
 15 
D380A, a well-studied glaucoma causing mutation, abolished Ca2+ binding and 
destabilized mOLF by ~7 °C, but no systematic mutational studies have been conducted 
to ascertain whether thermal stability arises due to the position of the residue rather than 
the specific amino acid side chain. For example, D478N is a documented glaucoma 
variant but the effect of this residue on mOLF stability was not known prior to this work. 
In addition, D478 has also not been systematically investigated, perhaps because there are 
no documented glaucoma mutations in this region. Notably, non-metal coordinating 
residues (alanine (human gOLF) and a serine (mouse gOLF)) are found in this position 
(Fig 3.1). We predicted that like D380A, mutation of D478 to these residues would 
abrogate Ca2+ binding to mOLF and destabilize the protein. Single point mutations 
(D380S, D380N, D478S, D478N, D478A, D380A/D478N, D380A/D478S) were 
successfully introduced into mOLF or mOLF(D380A) plasmids by SDM, expressed, 
purified, and biophysically characterized (See Chapter 3 for Methods and Materials).  
Table 3.1. Rationale behind chosen mutagenesis for mOLF. 
Mutation Rationale 
D380A Well studied glaucoma-causing mutant 
D380N Glaucoma-causing mutant not yet 
investigated 
D380S Parallels D478 
D478A Human gOLF contains an alanine 
D478N Documented glaucoma-causing variant 
D478S Mouse gOLF contains a serine 
D380A/D478N Documented glaucoma-causing variants; 
complete knockout of Ca2+ binding  




Figure 3.1. Multiple sequence alignment of OLF domain-containing proteins. Secondary 
structure and numbering scheme provided above alignments for mOLF. Arrows represent 
β-strands, helices represent α-helices, and T represents a β-turn. Reprinted by permission 
from Oxford University Press and Copyright Clearance Center. 
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WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
D478S       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
D478S       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN  
D478S       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN  
            ************************************************************ 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
D478S       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF  
            ************************************************************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
D478S       KNRYKYSSMISYNPLEKKLFAWDNLNMVTYDIKLSKM  
            **********.************************** 
Figure 3.2. DNA sequencing results for MBP-mOLF(D478S) plasmid. Raw data can be 
found in notebook #1 on pages 132 through 135. 
 
 
WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
D478N       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
D478N       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
D478N       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
            ************************************************************ 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
D478N       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
            ************************************************************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM 
D478N       KNRYKYSSMINYNPLEKKLFAWDNLNMVTYDIKLSKM 
            **********:************************** 
Figure 3.3. DNA sequencing results for MBP-mOLF(D478N) plasmid. Raw data can 
be found in notebook #2 on pages 108 and 109. 
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WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
D478A       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
D478A       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
D478A       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
            ************************************************************ 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
D478A       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
            ************************************************************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM 
D478A       KNRYKYSSMIAYNPLEKKLFAWDNLNMVTYDIKLSKM 
            ********** ************************** 
Figure 3.4. DNA sequencing results for MBP-mOLF(D478A) plasmid. Raw data can 
be found in notebook #3 on pages 13 and 14. 
 
WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
D380N       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
D380N       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
D380N       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDINLAVDEAGLWVIYSTDEAKGAIVLSKLN 
            ********************************:*************************** 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
D380N       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
            ************************************************************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM 
D380N       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM 
            ************************************* 
Figure 3.5. DNA sequencing results for MBP-mOLF(D380N) plasmid. Raw data can 
be found in Dr. Shannon Hill’s notebook #14 on page 91. 
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WTOLF       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
D380S       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
            ************************************************************ 
 
WTOLF       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
D380S       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
            ************************************************************ 
 
WTOLF       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
D380S       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDISLAVDEAGLWVIYSTDEAKGAIVLSKLN 
            ********************************.*************************** 
 
WTOLF       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
D380S       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
            ************************************************************ 
 
WTOLF       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM 
D380S       KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM 
            ************************************* 
Figure 3.6. DNA sequencing results for MBP-mOLF(D380S) plasmid. Raw data can 
be found in Dr. Shannon Hill’s notebook #14 on page 92. 
 
 
WTOLF        LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
D380A/       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR  
D478S        ************************************************************ 
 
WTOLF        IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
D380A/       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY  
D478S        ************************************************************ 
 
WTOLF        ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
D380A/       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIALAVDEAGLWVIYSTDEAKGAIVLSKLN 
D478S        ******************************** *************************** 
 
WTOLF        PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
D380A/       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
D478S        ************************************************************ 
 
WTOLF        KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM  
D380A/       KNRYKYSSMISYNPLEKKLFAWDNLNMVTYDIKLSKM  
D478S        **********.************************** 
Figure 3.7. DNA sequencing results for MBP-mOLF(D380A/D478S) plasmid. Raw data 
can be found in notebook #1 on pages 127 through 131. 
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WTOLF        LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
D380A/       LKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWR 
D478N        ************************************************************ 
 
WTOLF        IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
D380A/       IDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRY 
D478N        ************************************************************ 
 
WTOLF        ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLN 
D380A/       ELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIALAVDEAGLWVIYSTDEAKGAIVLSKLN 
D478N        ******************************** *************************** 
 
WTOLF        PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
D380A/       PENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPF 
D478N        ************************************************************ 
 
WTOLF        KNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM 
D380A/       KNRYKYSSMINYNPLEKKLFAWDNLNMVTYDIKLSKM 
D478N        **********:************************** 
Figure 3.8. DNA sequencing results for MBP-mOLF(D380A/D478N) plasmid. Raw 
data can be found in notebook #3 on page 12. 
 
Purification of mOLF Variants 
 Growth expression yields of each mOLF variant ranged from 5.4 g/L to 13.2 g/L 
(Table 3.2). Protein purification for each variant was similar, and involved lysing 3-9 g of 
MBP-mOLF-containing E. coli cell paste followed by a series of affinity and size 
exclusion chromatography steps. First, the fusion protein MBP-mOLF variants were 
isolated by amylose affinity column followed size exclusion separation on a sup75 
column. To remove the MBP tag, fusion proteins were subjected to overnight cleavage 
reactions at a 50:1 protein to Factor Xa ratio. To isolate mOLF variants, Factor Xa 
cleavage reaction mixtures were purified again on amylose affinity column in which the 
cleaved mOLF protein variants elute in the flowthrough, followed by a final polishing 
step by size exclusion chromatography. Purified mOLF monomer fractions were 
concentrated and buffer-exchanged in appropriate buffers to be used in thermal stability 
measurements, intrinsic fluorescence, and crystallization (see below). Figures 3.9 and 
3.10 illustrate sup75 chromatograms for mOLF variants before and after Factor Xa 
cleavage reactions. Purified protein yields ranged from 0.156 mg/g wet cell paste for 
 21 
mOLF(D480N) to 0.568 mg/g cell paste for mOLF(D478A) (Table 3.2). Purity of sup75 
fractions were assessed using 12% resolving SDS-PAGE for fusion MBP-mOLF variants 
and 15% resolving SDS-PAGE for cleaved mOLF variants (Fig 3.11-3.17). Cleaved 
mOLF protein has a size around 31 kDa and MBP aggregates were resolved around 45 
kDa. Relative amounts of MBP compared to purified protein were low after Factor Xa 
cleavage and a round of amylose affinity and sup75 size exclusion chromatography. 
Table 3.2. Growth expression yields and protein expression yields for mOLF variants. 
Olfactomedin Domain Cell Paste Yield (g/L) Protein Yield (mg/g cell 
paste) 
mOLF(D478S) 7.4 0.318 
mOLF(D478N) 5.4 0.167 
mOLF(D478A) 7.8 0.568 
mOLF(D380S) 6.5 0.176 
mOLF(D380N) 7.1 0.156 
mOLF(D380A/D478S) 6.5 0.225 
mOLF(D380A/D478N) 8.1 0.509 
 
 
Figure 3.9. Overlay of sup75 chromatograms for fusion mOLF variants located in the 
calcium binding site. The first eluted peaks are MBP-mOLF aggregates and the second 




Figure 3.10. Overlay of sup75 chromatograms for cleaved mOLF variants. The first 
eluted peak are mOLF aggregates and the second eluted peak contained cleaved mOLF 
protein. 
  
Figure 3.11. MBP-mOLF(D478S) purification assessment from size exclusion 
chromatography on sup75 column by 12% resolving SDS-PAGE (left). Cleaved 
mOLF(D478S) purification assessment from size exclusion chromatography on sup75 




Figure 3.12. MBP-mOLF(D478N) purification assessment from size exclusion 
chromatography on sup75 column by 12% resolving SDS-PAGE (left). Cleaved 
mOLF(D478N) purification assessment from size exclusion chromatography on sup75 
column by 15% resolving SDS-PAGE (right). 
 
Figure 3.13. MBP-mOLF(D478A) purification assessment from size exclusion 
chromatography on sup75 column by 12% resolving SDS-PAGE (left). Cleaved 
mOLF(D478A) purification assessment from size exclusion chromatography on sup75 
column by 15% resolving SDS-PAGE (right). 
 
Figure 3.14. MBP-mOLF(D380S) purification assessment from size exclusion 
chromatography on sup75 column by 12% resolving SDS-PAGE (left). Cleaved 
mOLF(D380S) purification assessment from size exclusion chromatography on sup75 
column by 15% resolving SDS-PAGE (right). 
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Figure 3.15. MBP-mOLF(D380N) purification assessment from size exclusion 
chromatography on sup75 column by 12% resolving SDS-PAGE (left). Cleaved 
mOLF(D380N) purification assessment from size exclusion chromatography on sup75 
column by 15% resolving SDS-PAGE (right). 
  
Figure 3.16. Cleaved mOLF(D380A/D478S) purification assessment from size exclusion 
chromatography on sup75 column by 15% resolving SDS-PAGE. Fusion protein size 




Figure 3.17. MBP-mOLF(D380A/D478N) purification assessment from size exclusion 
chromatography on sup75 column by 12% resolving SDS-PAGE (left). Cleaved 
mOLF(D380A/D478N) purification assessment from size exclusion chromatography on 
sup75 column by 15% resolving SDS-PAGE (right) 
 
Thermal Stability 
 The seven purified, cleaved, monomeric mOLF variants were evaluated for 
thermal stability using DSF which uses Sypro Orange dye to monitor the increase in 
hydrophobicity as the protein unfolds. mOLF variants were measured in triplicate with 
and without 10 mM CaCl2 as a convenient measure of residual calcium affinity. We 
expected that mOLF variants with a single point mutation at the D380 position would to 
be destabilizing since mOLF(D380A) is a disease-causing mutant21 exhibiting decreased 
stability (Tm = 46.6°C)19 and the D380 position is involved in coordinating the mOLF 
calcium ion19. Similarly, single point mutations at the D478 position of mOLF were also 
expected to be destabilizing since this residue is also involved in calcium coordination. 
Finally, since mutations at both D380 and D478 are expected to disrupt ion binding, the 
seven mOLF variants were not expected to exhibit a change in thermal stability in the 
presence of calcium.   
 Mutants at the D380 position behaved as expected, but results for mutants at 
D478 and the double mutants containing D380A and a mutation at D478, were 
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surprising. The stability of OLF(D380N) and mOLF(D380S) were both lower than that of 
WT mOLF (51.7 °C), comparable to the Tm for mOLF(D380A) (46.6 °C19, and these 
variants were inert to the presence of calcium (Table 3.3). By contrast, mOLF(D478A), 
mOLF(D478N), and mOLF(D478S) exhibited ~ 5-7 °C higher stability compared to WT 
mOLF, though calcium binding appeared to be effectively abolished. Even more 
shocking was the result for double mutants mOLF(D380A/D478S), 
mOLF(D380A/D478N), where the increase in stability is ~10°C higher than 
mOLF(D380A), rescuing mOLF(D380A) to higher than WT mOLF stability. In sum, 
based on these experiments D380 is a position highly sensitive to destabilization 
concomitant with loss of calcium binding, whereas D478, and calcium binding in general, 
are not intrinsically destabilizing to mOLF. Moreover, D478 has the capacity to rescue 
the destabilizing effect imparted by D380A. 
Table 3.3. Thermal stability measurements of purified, cleaved mOLF variants.  
Olfactomedin Domain  Tm (°C) ΔTm + Ca2+ 
gOLF 69.7 ± 0.1 -0.4 
mOLF 51.7 ± 0.3 +7.2 
mOLF(D380A) 46.6 ± 0.3 -1.5 
mOLF(D380N) 48.3 ± 0.1 +0.7 
 47.9 ± 0.2 +1.3 
mOLF(D380S) 45.7 ± 0.1 -0.1 
 45.7 ± 0.1 -0.1 
mOLF(D478A) 56.7 ± 0.1 +1.3 
 57.2 ± 0.1 +1.2 
mOLF(D478N) 53.8 ± 0.1 +0.4 
 56.4 ± 0.1 +0.5 
 56.4 ± 0.1 +0.2 
 56.4 ± 0.1 +0.3 
mOLF(D478S) 58.9 ± 0.1 -1.2 
 58.4 ± 0.1 -0.9 
mOLF(D380A/D478N) 55.2 ± 0.2 -1.5 
 55.4 ± 0.1 -1.6 
mOLF(D380A/D478S) 55.5 ± 0.2 -1.3 




 Following thermal stability measurements, mOLF(D478S) was evaluated for 
chemical stability compared to WT mOLF. Unfolding and refolding trials were 
conducted using urea, a chaotropic agent that disrupts hydrogen bonds that are involved 
in tertiary structure folding. As the purified proteins become denatured, the hydrophobic 
interior emits at certain peak wavelengths that were detected between 300-500 nm using 
an excitation wavelength of 284 nm. WT mOLF and mOLF(D478S) unfolding and 
refolding were measured in triplicate at each different condition with 9 collections per 
sample. We expected mOLF(D478S) to have increased chemical stability in comparison 
to WT since the variant had increased thermal ability. Refolding of WT mOLF was not 
expected to occur since previous members of the Lieberman lab were not able to refold 
the protein back to native structure. Refolding of mOLF(D478S) was expected to occur 
since the variant was found to increase thermal stability from a single point mutation that 
resembled gOLF, which has been found to be capable of refolding. 
 Chemical stability of mOLF(D478S) was increased in comparison to WT mOLF 
as expected, but refolding was observed for both WT and the D478 variant. Stability of 
mOLF(D478S) exhibited a 0.2 M urea concentration increase for unfolding compared 
with WT mOLF (Fig 3.18a). Refolding of mOLF(D478S) (Fig 3.18b) appeared to be 
more efficient than WT mOLF refolding (Fig 3.18c) as apparent by the alignment 
precision of the refolded peak emission wavelengths with the peak emission wavelengths 
of the protein before unfolding. To sum, a single point mutation at the calcium-
coordinated D478 position of mOLF was able to not only confer thermal stability of the 
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β-propeller structure, but it was also able to chemically stabilize the protein and more 
efficiently refold the denatured protein.  
(a.) (b.)  
(c.)  
Figure 3.18. Chemical unfolding and refolding curves of WT mOLF and mOLF(D478S) 
using urea. (a.) Overlayed comparison of fluorescence measurements as a function of 
urea concentration between WT and mOLF(D478S). Refolding of (b.) mOLF(D478S) 
and (c.) WT mOLF are represented by the red data points.   
 
Crystallization 
 We next pursued structure determination of thermally stabilizing mOLF(D478S), 
mOLF(D478N), and mOLF(D380A/D478S) to visualize structural changes in these 
variants that could account for increased stability of the mOLF β-propeller. X-ray 
crystallography provides a 3-D protein structure at the atomic level from diffracted beams 
of incident X-rays. A total of 9 optimization trays were setup for mOLF(D380A/D478S), 
10 trays for mOLF(D478S), and 12 trays for mOLF(D478N). Crystal morphology 
resembled small “gem stones” observed under a light microscope (Fig 3.19-3.21). Crystal 
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structures of all three proteins were solved and refined by Dr. Shannon Hill, research 
scientist in the Lieberman lab.  
A striking structural perturbation was revealed by all three ~ 2 Å resolution 
crystal structures solved by Dr. Hill. All three structures missing electron density for the 
helix and loops of Blade A (Fig 3.22), suggesting that these regions of the protein are not 
locked into a single conformation as they are in the WT structure. Thus, these structures 
apparently represent a partially folded state of mOLF. With a loss of helical secondary 
structure, this state would be expected to correspond to less, not more, stability compared 
to WT. 
 
Figure 3.19. Crystal images of mOLF(D380A/D478S). Purified protein was concentrated 
down to 15 mg/mL and the well conditions with optimal crystal growth were 20% PEG 
3350, 0.2 M BisTris, 0.2 M magnesium formate, and a 1:1 drop ratio. 
 
 
Figure 3.20. Crystal images of mOLF(D478S). Purified protein was concentrated down 
to 15 mg/mL and the well conditions with optimal crystal growth were 20% PEG 3350, 




Figure 3.21. Crystal image of mOLF(D478N). Purified protein was concentrated down to 
15 mg/mL and well conditions with optimal crystal growth were 20% PEG 3350, 0.2 M 
BisTris, 0.3 M magnesium formate, and a 1:1 drop ratio. 
(a.) (b.)  
Figure 3.22. (a.) Crystal structure of mOLF(D380A/D478S) with an Rwork of 0.2556, 
Rfree of 0.3169, and a resolution of 2.1 Å. Missing electron density in Blade A was 
consistent in all mOLF variants that contained a mutation at the D478 residue position. 
Missing electron density suggests that the amino acids in that region are flexible in 
solution. (b.) Structural overlay of WT mOLF (light pink), mOLF(D380A/D478S) 
(magenta), and mOLF(D478S) (green). Crystal structure of mOLF(D478S) had an Rwork 
of 0.1905, Rfree of 0.2308, and a resolution of 1.8 Å. Regions of missing electron density 
in the mOLF D478 variant structures are indicated by the boxed in areas. 
 
Solution Structural Characterization of Stabilized mOLF Variants 
 To confirm the crystallographic result of apparent increased flexibility of 
mOLF(D478S), mOLF(D478N), and mOLF(D380A/D478S) resulting in missing 
electron density, near-UV circular dichroism (CD) was used to characterize and compare 
the tertiary structure with WT mOLF in solution. This method measures absorption of 
circularly polarized light by aromatic amino acid residues and serves as a readout of local 
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chemical environment. Phenylalanine are detected between 250-270 nm, tyrosine 
between 270-290 nm, and Tryptophan between 280-300 nm. In areas corresponding to 
missing electron density, shown in red (Fig 3.23), there are three aromatic amino acid 
residues, two Tyr and one Phe. Therefore, mOLF variants with increased flexibility were 
predicted to have deviations from WT in the Phe/Tyr region of the CD spectrum but 
minimal deviation in the lower energy Trp region.  
 CD spectra of mOLF(D478S), mOLF(D478A), mOLF(D380A/D478S), and 
mOLF(D380A/D478S) revealed deviations from WT mOLF spectra in the 250-290 nm 
range of phenylalanine and tyrosine residues (Fig 3.24), indicating non-native structures 
and adding further evidence that the amino acid residues missing electron density in the 
three crystal structures are more flexible in solution. The variant spectra are similar to CD 
spectra of destabilizing mOLF(D380A). Notably, the mOLF(D380A) CD spectrum had 
deviations from WT mOLF within the tryptophan region that appear to be corrected in 
the double mutant mOLF(D380A/D478S) and mOLF(D380A/D478N). These results 
suggest that the destabilized non-native structure imparted by D380A in mOLF can be 
partially rescued by a single point mutation in the D478 position.   
 To further confirm the crystallographic result, intrinsic fluorescence 
measurements were conducted on mOLF variants (Fig 3.25). This method monitors the 
environment of aromatic residues: when tryptophan and tyrosine residues become more 
surface-exposed, hydrogen bonding causes a shift to longer emission wavelengths. Based 
on the structures and CD spectra, we predicted a shift to longer wavelengths for the 
mOLF variants compared to WT. Indeed, both stabilizing mOLF mutants (D478S, 
D478A, D380A/D478N) and destabilizing mOLF mutants (D380N and D380S) exhibited 
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red-shifted fluorescence emission maxima (~338-342 nm) compared to WT mOLF (<336 
nm). In sum, though it remains a mystery why some mutations are thermally stabilizing 
and others destabilizing, solution biophysical measurements confirm a non-native 
structure of mOLF variants at positions D380 and D478 in solution.  
Figure 3.23. Amino acid sequence of mOLF. Regions of missing electron density in the 
D478 variant structures are indicated by the red amino acid residues. Bolded amino acid 




Figure 3.24. Near-UV CD spectra overlay of WT (black), mOLF(D380A) (blue solid), 
mOLF(D380N) (blue dotted), mOLF(D380S) (blue dash), mOLF(D478A) (red dotted), 
mOLF(D478S) (red dash), mOLF(D478N) (red solid), mOLF(D380A/D478N) (green 








Figure 3.25. Intrinisic fluorescence measurement comparison of WT mOLF, 
mOLF(D478A), mOLF(D478N), mOLF(D478S), mOLF(D380N), mOLF(D380S), 
mOLF(D380A/D478N), and mOLF(D380A/D478S). 
 
Cellular Secretion of Stabilizing mOLF Variants 
 One of the current leading molecular mechanisms for myocilin-associated 
glaucoma involves intracellular aggregation of misfolded myocilin disease variants, 
particularly within the ER, instead of secretion of myocilin to the TM in the anterior 
segment of the eye22. This aggregated protein buildup leads to ER stress, cell death6, 15, 23. 
Decreased fluid outflow from the TM is proposed to lead to accelerated increase of 
intraocular pressure and cause vision loss and glaucoma, particularly in children15. The 
Lieberman lab in collaboration with Chad Dickey’s lab (University of South Florida) 
previously confirmed earlier results regarding robust secretion of WT myocilin and 
intracellular sequestration of disease-associated myocilin mutants in a model cell culture 
system24. The cellular behavior of the thermally stabilized, yet partially unfolded, D478 
variants was not readily predicted, since the relative importance of stability and structure 
for cellular quality control and secretion has not been tested.  
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Therefore, the Dickey lab evaluated the cellular secretion profiles of WT, D380A, 
D478S, D478N, and D380A/D478N full-length myocilin variants, detecting extracellular 
(Fig 3.26) and intracellular levels of myocilin (Fig 3.27). For intracellular myocilin, 
analysis included solubility with and without Triton-X100, a commonly used detergent 
for solubilizing non-amyloid aggregates. Stabilized, non-native single point mutants, 
D478S and D478N on their own, and as double mutants with D380A exhibited 
extracellular secretion profiles similar to WT mOLF. Consistent with this result, only 
intracellularly-sequestered D380A were insoluble in Triton-X100. Thus, thermal stability 
appears to be the key parameter for proper secretion of myocilin, more so than native 












































Figure 3.26. Extracellular secretion profiles of WT, D380A, D478S, D478N, and 
D380A/D478N myocilin. Disease-causing variant D380A is known to be prone to 






















































































Figure 3.27. Solubility of intracellular myocilin in Triton X-100 detergent. Insoluble 
protein was observed only with the disease-causing D380A variant which is known to be 
prone to aggregation. 
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CHAPTER 4 
EXPERIMENTAL PROCEDURES AND MATERIALS 
Molecular biology 
 The parent WT mOLF plasmid was synthesized as previously reported25. Briefly, 
the mOLF gene corresponding to amino acid residues 228-504 of full-length human 
myocilin was amplified and annealed into pET-30 Xa/LIC vector (Novagen) and then 
subcloned into pMAL-c5x vector. The mOLF pMAL-c5x vector produces mOLF as a 
fusion protein with MBP which can be removed using the intervening Factor Xa cleavage 
site (EIGR) within the linker.  
 Variants of mOLF were prepared using the parent mOLF plasmid using SDM 
(QuikChange Lightening kit). Forward and reverse primers (Table 4.1) specific for each 
mOLF variant were designed using Agilent Technologies QuikChange Primer Design 
(http://www.genomics.agilent.com/primerDesignProgram.jsp) and purchased from MWG 
Operon.   
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Table 4.1. Forward and reverse primer designs for all mOLF variants in this study. 
Mutation Primers for Site Directed Mutagenesis 
F307L Fwd 5’-AGTATGACCTCATCAGCCAGTTAATGCAGGGCTAC-3’ 
Rev 5’-GTAGCCCTGCATTAACTGGCTGATGAGGTCATACT-3’ 
K358L Fwd 5’-GAGACAGTGAAGGCTGAGCTAGAAATCCCTGGAGCTGGC-3’ 
Rev 5’-GCCAGCTCCAGGGATTTCTAGCTCAGCCTTCACTGTCTC-3’ 
D378Y Fwd 5’-TCCACAGCCAAGTCAATATACGTGTAGCCACCCCAAG-3’ 
Rev 5’-CTTGGGGTGGCTACACGTATATTGACTTGGCTGTGGA-3’ 
D380N Fwd 5’-TGGGGTGGCTACACGGACATTAACTTGGCTGTG-3’ 
Rev 5’-CACAGCCAAGTTAATGTCCGTGTAGCCACCCCA-3’ 
D380S Fwd 5’-TGGGGTGGCTACACGGACATTAGCTTGGCTGTGGA-3’ 
Rev 5’-TCCACAGCCAAGCTAATGTCCGTGTAGCCACCCCA-3’ 
S404A Fwd 5’-CTGGGTTCAGTTTGGCGAGGACAATGGCACC-3’ 
Rev 5’-GGTGCCATTGTCCTCGCCAAACTGAACCCAG-3’ 
T455L Fwd 5’-GCTGATACCTGTGCCTAAGTCATAAGCAAAGTTGACGGTA-3’ 
Rev 5’-TACCGTCAACTTTGCTTATGACTTAGGCACAGGTATCAGC-3’ 
G456L Fwd 5’-CTTGCTGATACCTGTTAGTGTGTCATAAGCAAAGTTGACGGTAGCAT-3’ 
Rev 5’-ATGCTACCGTCAACTTTGCTTATGACACACTAACAGGTATCAGCAAG-3’ 
D478A Fwd 5’-GCAGCATGATTGCGTACAACCCCCTG-3’ 
Rev 5’-CAGGGGGTTGTACGCAATCATGCTGC-3’ 
D478N Fwd 5’-CGCTATAAGTACAGCAGCATGATTAACTACAACCCCCT-3’ 
Rev 5’-AGGGGGTTGTAGTTAATCATGCTGCTGTACTTATAGCG-3’ 
D478S Fwd 5’-CCGCTATAAGTACAGCAGCATGATTAGCTACAACCCCCTGG-3’ 
Rev 5’-CCAGGGGGTTGTAGCTAATCATGCTGCTGTACTTATAGCGG-3’ 
Primers were dissolved using the appropriate amount of nuclease free water indicated by 
Operon to yield a final primer concentrations of 100 μM. Forward and reverse primers 
were subsequently diluted to 125 ng/μL in 10 μL reaction volumes. mOLF plasmids were 
diluted to 50 ng/μL and 10 ng/μL in 5 μL reaction volumes. The following reagents were 
mixed together to end up with a total reaction volume of 50 μL in a polymerase chain 
reaction (PCR) tube: 
 dNTP (1 μL) 
 10x reaction buffer/QC L Buffer (5 μL) 
 Plasmid (1 μL) 
 Forward primer (1μL) 
 Reverse primer (1 μL) 
 QuikSolution reagent (1.5 μL) 
 DMSO (1 μL) 
 RNAse free H2O (37.5 μL) 
 QuikChange Lightning Enzyme (1 μL) 
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Each of the reactions are placed in an S1000 Thermal Cycler (Bio-Rad) using the 
following parameters: 
Cycles Temperature Time 
1 95°C 2 minutes 
18 95°C 20 seconds 
68°C 10 seconds 
68°C 3.5 minutes 
After the reaction came to completion, 50 μL of Membrane Binding Solution 
containing ethanol (Promega) was added to the PCR amplification and then transferred to 
a SV Minicolumn-Collection Tube for 1 min incubation at room temperature. Then, the 
Minicolumn assembly was centrifuged at 16,000 x g for 1 minute followed by an addition 
of 700 μL of Membrane Wash Solution (Promega) containing ethanol. These steps were 
repeated with 500 μL of Membrane Wash Solution and centrifuged for 5 minutes. To 
allow for any residual ethanol to evaporate, the Minicolumn assembly was centrifuged 
for 1 minute and then transferred to a new 1.5 mL microcentrifuge tube where 50 μL of 
nuclease free water was added to the minicolumn, incubated at room temperature for 1 
minute, and centrifuged for 1 minute. 
 Once all the amplification reactions were washed, 2 μL of Dpn I restriction 
enzyme was directly added to each of the reactions and incubated at 37°C for 10 minutes. 
A 2 μL aliquot of Dpn I-treated DNA was added to 45 μL of XL10-Gold ultracompetent 
cells and 2 μL of β-Mercaptoethanol in a chilled 14-mL BD Falcon polypropylene round-
bottom tube and incubated on ice for 30 minutes. The reactions were then heat-shocked 
in a 42°C water bath for exactly 30 seconds and then incubated on ice for 2 minutes. 
Preheated aliquots of super optimal broth with catabolite repression (SOC) medium were 
added to each reaction tube and incubated in the 37°C shaking incubator (225-250 rpm) 
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for 1 hour. After incubation, approximately 250 μL of each reaction was plated onto agar 
plates containing 60 μg/mL ampicillin (AMP) and incubated upside down overnight in a 
37°C incubator. 
 DNA plasmids were isolated for sequencing to confirm mutagenesis for mOLF 
variants via minipreparation (miniprep). A single colony from each transformation 
reaction was added to 20 mL of sterilized Luria Broth (LB) containing 60 μg/mL AMP 
added for overnight growth in a 37°C shaking incubator (220-225 rpm). Small-scale 
growths were then centrifuged (4500 rpm) for 20 minutes followed by resuspension of 
the pelleted cells into 500 μL of P1 buffer from the QIAprep Spin Miniprep Kit 250 
(Qiagen). Resuspended cells were transferred to a 2 mL microcentrifuge tube and 
combined with 500 μL of P2 buffer and 700 μL of N3 buffer also from the Qiagen 
Miniprep Kit. Reaction mixtures were centrifuged (13000 rpm) for 20 minutes followed 
by 1 minute spins (13000 rpm) with supernatant applied to QIAprep Spin columns. The 
miniprep columns were washed with 500 μL of PB buffer followed by 750 μL of PE 
buffer for 1 minute spins each (13000 rpm). The column was then transferred to a new 
microcentrifuge tube to elute the DNA with 50 μL of nuclease free water. All isolated 
MBP-mOLF variant plasmids were verified by DNA sequencing (MWG Operon). 
Protein expression 
Plasmids were transformed into Rosetta-Gami 2 (DE3) competent cells onto agar 
plates containing 60 μg/mL AMP plus 34 μg/mL chloramphenicol (CAM) selective LB. 
Plates were placed upside down in a 37°C incubator for overnight growth. Starter 
cultures were prepared by adding one bacterial colony of the mOLF variant to 250 mL of 
LB media containing selective AMP/CAM antibiotics and the solution was incubated at 
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37°C with shaking overnight (225-250 rpm). For large scale cultures, 25 mL of the starter 
culture was used to inoculate each 1L solution of Superior broth in 2L baffled flasks, and 
the solutions were allowed to grow at 37°C in a shaking incubator (225-250 rpm) until 
the cells reached an optical density (OD) of ~1.5-1.7 measured at 600 nm. A total of 3L 
were grown for large scale cultures. At this point, the temperature was reduced to 18°C, 
flasks equilibrated for 1.5 h at 18 °C at which point protein expression was induced with 
500 μM isopropyl β-D-thiogalactopyranoside (IPTG). The cells continued to incubate 
overnight at 18ºC for 16-18 hours. The next day, the cells were harvested by 
centrifugation (2380g) with 10 minute spins, flash-frozen with liquid nitrogen, and stored 
at -80°C. 
Purification of mOLF variants 
 Cell paste (3 g) containing MBP-mOLF variants was resuspended in 10 mL 
amylose wash buffer (10 mM Na2HPO4, 10 mM KH2PO4, 200 mM NaCl, 1 mM EDTA) 
and 1X Roche Complete Protease Inhibitor Cocktail tablets and lysed by passage through 
a French Press twice. Cell debris was removed by centrifugation at 161,716g at 4°C for 
45 minutes to remove cell debris. The soluble fraction was loaded onto an amylose 
affinity column (New England Biolabs) equilibrated with amylose wash buffer, and 
MBP-mOLF fusion protein was eluted with amylose elution buffer (10 mM Na2HPO4, 10 
mM KH2PO4, 200 mM NaCl, 1 mM EDTA, 10 mM Maltose). Final fractionation using a 
Superdex 75 (GE Healthcare) size-exclusion column equilibrated with gel filtration 
buffer (200 mM NaCl, 10 mM Na2HPO4, 10 mM KH2PO4) isolated monomeric MBP-
mOLF variants. MBP-mOLF variants with protein concentrations around 20 mg/mL were 
then cleaved with 1 mg/mL Factor Xa in gel filtration buffer (New England Biolabs) in a 
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50:1 protein to Factor Xa 10 mL reaction solution for 18 hours at room temperature. 
Amylose affinity chromatography was then used to separate cleaved mOLF variants, 
which elute in the flow-through, from uncleaved MBP-mOLF and free MBP, which bind 
the column. The mOLF variants were further polished by a final sup75 step followed by 
purity assessment with a 15% resolving SDS-PAGE. 
Thermal stability measurements 
 Each mOLF variant was tested for thermal stability via DSF25. Sypro Orange 
(Invitrogen), a dye that is known to bind to the hydrophobic regions of proteins, was 
supplied as 5000 X solution in dimethylsulfoxide and was diluted in water (1:100) prior 
to preparation of the samples. Purified mOLFs were buffer exchanged into 10 mM 
HEPES pH 7.5 and 200 mM NaCl by concentrating and diluting three times using an 
Amicon MWCO 10K filtration device. Reactions mixtures (30 μL) containing 3 μL of 
diluted Sypro Orange and a final protein concentration of 3 μM were prepared in 
triplicate at room temperature with or without 10 mM CaCl2. Samples were placed in a 
96-well optical plate (Applied Biosystems) and sealed with optical film. Fluorescence 
measurements from DSF were obtained on Applied Biosciences Step-One Plus real time 
(RT)-PCR instrument to conduct a slow melt. Melts were conducted from 25 – 95 °C 
with a 1 °C per minute increase. Data was analyzed using OriginLab Corporation 
software. The Tm was calculated at the midpoint of unfolding using a Boltzmann sigmoid 
equation. Reported values are an average of two independent experiments. 
Chemical unfolding experiments 
 WT and mOLF(D478S) chemical stability measurements were compared by 
unfolding both proteins using the chaotropic agent urea. Urea works to disrupt hydrogen 
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bonds that contribute to the folding of the tertiary structure to promote denaturation of the 
protein and expose the hydrophobic interior of the protein that emit at certain 
wavelengths. Stocks of 9 M urea, 10 μM purified protein, and a 10 mM Na/K phosphate 












0 1 0 90 10 
0.25 1 2.8 87.2 10 
0.5 1 5.6 84.4 10 
1 1 11.1 78.9 10 
2 1 22.2 67.8 10 
3 1 33.3 56.7 10 
4 1 44.4 45.6 10 
5 1 55.5 34.5 10 
6 1 66.6 23.4 10 
7 1 77.8 12.2 10 
8 1 88.9 1.1 10 
Each sample condition was prepared in triplicate and were placed in 4°C for at least 1 
hour prior to measurement. All samples were measured on a Shimadzu RF-5301PC 
spectrofluorophotometer at an excitation wavelength of 284 nm, an emission wavelength 
range of 300 to 500 nm, 5 nm slit-widths on excitation and emission monochromators 
with 0.2 nm data intervals for 9 data collections. 
Intrinsic fluorescence measurements 
 Purified mOLFs (WT, D380A, D380N, D380S, D478A, D478N, D478S, 
D380A/D478N, and D380A/D478S) were concentrated in 10 mM Na/K phosphate pH 
7.2, 0.2 M NaCl buffer to compare the intrinsic fluorescence of surface exposed amino 
acid residues. A 1 μM sample of each purified mOLF variant was measured on a 
Shimadzu RF-5301PC spectrofluorophotometer at an excitation wavelength of 284 nm, 
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an emission wavelength range of 300 to 500 nm, 5 nm slit-widths on excitation and 
emission monochromators with 0.2 nm data intervals for 9 data collections. Each variant 
was measured in triplicate. Reported values are an average of two independent 
experiments. 
Circular dichroism 
 Near-UV CD measurements were acquired on a Jasco J-815 spectropolarimeter 
equipped with a Jasco PTC-4245/15 temperature control system. mOLF samples at a 
concentration range between 1.0 - 3.5 mg/mL were measured in 10 mM Na/K phosphate 
pH 7.2, 0.2 M NaCl buffer at 4 ° C. Scans were measured from 250 nm to 320 nm at a 
rate of 50 nm/min and a data pitch of 1 nm using a 0.1 cm cuvette. Each measurement 
was an average of 20 scans.  Data were blank-subtracted and converted to mean residue 
ellipticity Θ= Mres×Θobs/ 10 ×d ×c, where Mres=112.9 is the mean residue mass 
calculated from the protein sequence; Θobs is the observed ellipticity (degrees) at 
wavelength λ; d is the pathlength (cm); and c is the protein concentration (g/ml). The 
reported spectra are an average of two independent measurements. 
Crystallization of mOLF(D478S), mOLF(D478N), and mOLF(D380A/D478S) 
 Crystallization of mOLF(D478S), mOLF(D478N), and mOLF(D380A/D478S) 
concentrated to 15 mg/mL in 10 mM Hepes pH 7.5 were optimized from the condition 
used to crystallize purified selenomethionine (SeMet)-substituted mOLF E396D15. 
Crystals were grown by hanging drop method at room temperature with a 1:1 drop ratio 
of well solution to protein. mOLF(D478S) crystals and mOLF(D380A/D478S) crystals 
were grown in 20% PEG 3350, 0.2M BisTris, 0.2 M magnesium formate and were 
cryprotected in 20% PEG 3350, 0.2M BisTris, 0.2 M magnesium formate, 20% glycerol.  
 43 
mOLF(D478N) crystals were grown in 20% PEG 3350, 0.2 M BisTris, 0.3 M magnesium 
formate and were cryoprotected in 15% PEG 3350, 0.1 M BisTris, 0.1 M magnesium 
formate, 25% glycerol. Diffraction data were collected at the Southeast Regional 
Collaborative Access Team (SER-CAT) 22-ID beamline and processed using HKL-
200026. The D380A/D478S structure was solved by molecular replacement using 
Phaser27 with the myocilin olfactomedin domain E396D crystal structure (PDB code 
4WXS) as the search model, followed by Phenix Auto build28.  The mOLF(D478S) and 
mOLF(D478N) structures were solved by molecular replacement using the refined 
mOLF(D380A/D478S) structure as the search model in Phaser. The models were 
iteratively built and refined using Coot29 and Phenix.refine30. 
Cellular secretion of stabilizing mOLF variants 
 HEK 293T cells were grown and maintained in Dulbecco's modified Eagle's 
Medium supplemented with 10% FBS (Sigma), 1% Sodium Pyruvate (Corning) and 1% 
GlutaMAX (Invitrogen) at 37°C under 5% CO2. 6.5 * 10
5 cells/well were plated 24 hours 
prior to DNA transfection. Plasmid transfections were carried out in serum-free opti-mem 
(Invitrogen) medium via lipofection. 1µg: 2.5 µl ratio of Plasmid: Lipofectamine 2000 
was used. Cells were transfected for 48 hours prior to harvest. The cells were harvested in 
Mammalian Protein Extraction Reagent (M-PER) buffer (Pierce) containing 1× protease 
inhibitor mixture (Calbiochem), 100 mM phenylmethylsulfonyl fluoride, and 1× 
phosphatase inhibitor II and III mixtures (Sigma). 
 Equal amounts of protein from cell lysates were prepared with 2× Laemmli 
sample buffer (Bio-Rad) with 2-Mercaptoethanol (BME) and denatured by boiling for 5 
min at 100°C. Prepared lysates were then loaded onto a 10% Tris–glycine SDS-PAGE. 
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Gels were transferred onto PVDF membranes (Millipore) and blocked for 1 h at room 
temperature with 7% milk. Media from cells were collected and spun at 10,000g for 10 
min. 200µl from each sample was added into each well of the dot blot apparatus and 
suctioned onto a nitrocellulose membrane. The membrane was then washed with PBS 
(filtered) twice and placed on Ponceau S. The membrane was blocked with 7% milk. 
Myocilin poly-clonal antibody was a gift from Dr. Stamer (Duke, North Carolina). 
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) antibody was purchased from 
Meridian Life Science (Saco, ME, USA). Actin antibody was purchased from Sigma. 
Secondary antibodies were all HRP-linked and purchased from Southern Biotechnolofies 
(Birmingham, AL, USA). All antibodies were added to blots in a 1:3000 dilution in 7% 
milk. Cellular secretion studies were completed by Amirthaa Suntharalingam from Chad 
Dickey’s lab (University of South Florida). 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS FOR A 
THERMOSTABLE OLFACTOMEDIN DOMAIN OF MYOCILIN 
The newly available structures of closely related OLF domain-containing proteins 
have given us clues into the molecular details of disease involvement as well as the 
evolution of the β-propeller structure of OLF domains15-16. Sequence divergence across 
surface residues of OLF domains suggests that these proteins have unique binding 
partners and, therefore, distinct functions16. By contrast, sequence conservation in the 
internal region is much higher across the domain family, leading to the prediction that 
OLF proteins should have similar biophysical properties. Yet, the more phylogenetically 
primitive gOLF lacks a calcium binding site common among OLF domain family 
members and is significantly more stable than mOLF.  
In line with previous efforts on engineering β-propeller structures that stressed the 
importance of hydrophobic interactions in the context of structural stability and proper 
protein folding20, we first tested the hypothesis that increased hydrophobic interactions in 
gOLF confer its high thermal stability. Efforts to increase the thermal stability of the 
mOLF β-propeller by increasing hydrophobic interactions using residues similar to gOLF 
were met with lower thermal stability. It is possible that single point mutations in mOLF 
to residues in gOLF are insufficient to increase the global hydrophobic interactions 
needed to increase thermal stability. Additional studies will be needed to examine the 
additive effect of multiple simultaneous mutations on the overall hydrophobicity and thus 
stability of mOLF.  
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Remarkably, we discovered that mutations at a single position in mOLF, D478, 
result in a more stable protein that has lost the capability to bind calcium, yet exhibited 
new unstructured regions in mOLF. When the calcium ligand D478 was mutated to the 
corresponding residue in gOLF, thermal stability and resistance to chemical unfolding 
were increased. This result is in stark contrast to the nearly 40 other point mutations 
introduced into mOLF by the Lieberman lab which either had no effect on stability or 
were destabilizing, a hallmark of disease variants16, 19, 25. The combination of the 
mOLF(D478S) mutation with a disease-causing, destabilized variant mOLF(D380A) 
resulted in near WT stability and rescued secretion in a cell culture model, even though 
the molecular structure was not native. An interesting next step would be to test whether 
the effect is specific to the residue D380 or if the mOLF(D478S) variant can rescue the 
stability of other known disease-causing mOLF mutations. 
Since the identification of distinct metal binding sites in the β-propeller central 
cavity of mOLF and gOLF16, the role of these ions in stability of the β-propeller 
structures has been of intrigue with respect to the function and evolution of the OLF β-
propeller. As previously demonstrated in our lab, the disease-causing mOLF(D380A) 
variant is a moderately unstable protein with non-native tertiary structure that is prone to 
forming fibrils31. Thus, calcium provides a more stabilizing role in the propeller that 
affects the morphology and electrostatics that are involved in intermolecular 
interactions31, and perhaps helping the protein resist biomechanical stressors in the TM19. 
However, our findings in this study with mutants at position D478 in mOLF pose an 
interesting observation that the calcium ion is not necessary for proper folding of the 
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domain. A next step in this study would be probe additional sites on mOLF that allow 
mOLF to be converted to a protein of gOLF stability but with WT structure.  
The cumulative results of this study suggest that during evolution the calcium 
binding site was introduced at the cost of thermal stability. In the case of mOLF, the 
resulting protein in the eye is highly aggregation prone and causes glaucoma. Could the 
calcium binding in the cavity of mOLF be an evolutionary tradeoff for an acquired 
functional role in signaling, e.g. for cell-cell communication32? If this is the case, 
knockout of the calcium binding site with D478S in myocilin might disrupt downstream 
responses to calcium ion flux. Future work probing the effects of myocilin(D478S) in cell 
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